Latest Breaking News On - Psoriasis area - Page 1 : comparemela.com

Specific Inflammatory Markers Linked to Depression in Patients with Psoriasis

Specific Inflammatory Markers Linked to Depression in Patients with Psoriasis
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Greece
Athens
Attikír
Eleni-mitsiou
Aristotle-university-school-of-medicine
Aristole-university-of-thessaloniki
Department-of-dermatology
Aristotle-university-school
Papageorgiou-hospital
Psoriasis-outpatient-clinic
Aristole-university
Beck-depression

Greater Salivary Rates Linked to Lower Levels of Psoriasis Disease Severity

Greater Salivary Rates Linked to Lower Levels of Psoriasis Disease Severity
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

India
Ravi-kant-sharma
Mm-institute-of-medical-sciences
Dermatology-department
Maharishi-markandeshwar
Medical-sciences
Psoriasis-area
Severity-index

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all.

Suzhou
Jiangsu
China
Shanghai
Yulin-shi
Shaanxi
Chinese
Eli-lilly
Adimab-incyte
Innovent-biologics
National-medical-product-administration
Prnewswire-innovent-biologics-inc

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.

Shanghai
China
Yulin-shi
Shaanxi
Suzhou
Jiangsu
Chinese
Eli-lilly
Adimab-incyte
Innovent-biologics
Md-anderson-cancer-center
Linkedin

Innovent looks to Chinese regulators after ph. 3 psoriasis win

Innovent looks to Chinese regulators after ph. 3 psoriasis win
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

China
Chinese
Abbvie-skyrizi
Johnson-tremfya
Sun-pharma-ilumya
Amgen-tepezza
Eli-lilly
Psoriasis-area
Severity-index
Sun-pharma
Lei-qian
Protagonist-therapeutics-partnered